In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented key findings from the DELTA 3 trial at the prestigious 82nd American Academy of Dermatology (AAD) Congress in San Diego, California. This marks the first public disclosure of the results […]
LEO Pharma A/S said that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for delgocitinib cream. Touted as a groundbreaking topical pan-Janus kinase (JAK) inhibitor, this cream is specifically designed for adult patients battling moderate to severe chronic hand eczema (CHE). This validation kicks off the official review process by the […]
